Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Director/PDMR Shareholding
August 22, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)
Notification of transaction by person discharging managerial responsibilities
| 1. | Details of the person discharging managerial responsibilities ("PDMR") / person closely associated them ("PCA") | ||
| a) | Name | Flemming Ornskov | |
| 2. | Reason for the notification | ||
| a) | Position / status | Chief Executive Officer - PDMR | |
| b) | Initial notification / amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Shire plc | |
| b) | LEI | 54930005LQRLI2UXRQ59 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Shire plc Ordinary Shares of 5 pence each ("Ordinary Shares") | |
| Identification code | ISIN: JE00B2QKY057 | ||
| b) | Nature of the transaction | Acquisition of Ordinary Shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| £36.6493 | 8,400 | ||
| d) | Aggregated information - Aggregated volume - Price | N/A (single transaction) | |
| e) | Date of the transaction | August 22, 2017 | |
| f) | Place of the transaction | London Stock Exchange | |
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
| Investor Relations | ||
| Ian Karp | [email protected] | +1 781 482 9018 |
| Robert Coates | [email protected] | +44 1256 894874 |
| Media | ||
| Lisa Adler | [email protected] | +1 617 588 8607 |
| Debbi Ford | [email protected] | +1 617 949 9083 |
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
